Provided by Tiger Trade Technology Pte. Ltd.

SBP GROUP

5.710
+0.1602.88%
Volume:91.38M
Turnover:522.19M
Market Cap:106.68B
PE:37.65
High:5.800
Open:5.485
Low:5.485
Close:5.550
52wk High:8.335
52wk Low:4.136
Shares:18.68B
HK Float Shares:18.68B
Volume Ratio:1.54
T/O Rate:0.49%
Dividend:0.12
Dividend Rate:2.10%
EPS(LYR):0.152
ROE:14.07%
ROA:7.51%
PB:2.80
PE(LYR):37.65
PS:2.71

Loading ...

Sino Biopharma Gets US FDA Investigational New Drug Approval for Tumor Drug

MT Newswires Live
·
Sep 04

Sino Biopharm Says FDA Clears IND for Tqb6426 GPC3 ADC Trial in Advanced Tumors

Reuters
·
Sep 03

Sino Biopharmaceutical - Application for Clinical Trial on Tqb6426 "Gpc3 ADC" Approved by FDA

THOMSON REUTERS
·
Sep 03

Sino Biopharmaceutical Stock Rises 6.3% in Hong Kong, Outperforms Competitors

Dow Jones
·
Sep 03

SBP Group Surges Over 4% in Morning Trade on FDA Clearance for TQB6426

Deep News
·
Sep 03

Movement Alert|SBP GROUP Rises 3.33% in Regular Trading, Core ADC Drug TQB2102 Phase III Trial Hits Primary Endpoint

Market Focus
·
Sep 03

Sino Biopharm Files HKEX Next-Day Return Disclosing Share Buyback for Cancellation

Reuters
·
Sep 01

SBP Group Reports No Share Changes in August; 14.60 Million Shares Earmarked for Future M&A Payout

Bulletin Express
·
Sep 01

Sino Biopharma Unit Enters License, Supply Contract for Cancer Drug

MT Newswires Live
·
Aug 31

SBP Group inks exclusive pact with Cipla for novel HER2-targeting ADC

Stock News
·
Aug 31

Sino Biopharma Licenses HER2 ADC Tqb2102 to Cipla for India, South Africa, Other Emerging Markets in Deal Worth up to USD 123 Million

Reuters
·
Aug 31

Sino Biopharmaceutical - Cipla Granted Exclusive License for Tqb2102 in India, South Africa and Five Markets

THOMSON REUTERS
·
Aug 31

Sino Biopharmaceutical - Group Eligible for up to $123 Mln in Milestone Payments and Tiered Double-Digit Royalties

THOMSON REUTERS
·
Aug 31

Cipla and SBP Group Sign Exclusive Licensing Agreement for HER2 Bispecific Antibody-Drug Conjugate

Reuters
·
Aug 31

Sino Biopharmaceutical Stock Sheds 2.6% in Hong Kong

Dow Jones
·
Aug 31

Movement Alert|SBP GROUP Falls 3.04% in Regular Trading, Trading at HK$5.425

Market Focus
·
Aug 31

SBP Group Unveils Phase I Data: Single-Dose Kylo-11 Achieves Up to 97% Sustained Lp(a) Reduction

Bulletin Express
·
Aug 31

SBP Group Secures NMPA and FDA Green Lights for LM-364 “Nectin-4TME ADC” Clinical Trials

Bulletin Express
·
Aug 28

Sino Biopharm Wins NMPA Nod to Start LM-364 Nectin-4 TME ADC Trial in Solid Tumors

Reuters
·
Aug 28

Sino Biopharmaceutical - Lm-364 'Nectin-4Tme ADC' Receives Nmpa Clinical Trial Approval for Advanced Solid Tumors

THOMSON REUTERS
·
Aug 28